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ACR50 criteria with each of the drugs compared. NNTs calcu-
lated as the inverse of the Absolute Risk Reduction, have been
derived using results according to intention-to-treat from a ran-
domised controlled trial (US310) comparing 20 mg daily of
leﬂunomide with 7.15–15 mg weekly of metotrexate, adminis-
tered during 1 year. Considered annual treatment costs related
with the costs of the drug administered the consultations and lab
tests performed for routine monitoring, according to the infor-
mation provided by the manufactures in their summary of
product characteristics. Unitary costs have been obtained from
Spanish cost databases. RESULTS: Using the ACR20 criteria
NNTs with leﬂunomide and metotrexate SC are 4 (95% CI
2.56–7.71) and 5 (95% CI 3.03–14.3) respectively. Using the
ACR50 criteria NNTs are 4 (95% CI 2.72–6.54) and 7 (95% CI
4.03–19.3). The annual cost of each treatment per patient-year
(drugs and monitoring) equals 1793.3€ in case of leﬂunomide
and 2149.2€ for metotrexate SC. Combining these results the
cost of a controlled patient according to ACR20 amounts 7173€
for leﬂunomide and 10,746€ for metotrexate SC. Results accord-
ing to ACR50 equals 7173€ and 15044€ respectively. CONCLU-
SION: From the Spanish National Health System perspective and
effectiveness measured as respondent according to ACR20 the
use of leﬂunomide for patients with Rheumatoid Arthritis could
achieve important cost savings compared with the administration
of metotrexate SC. The savings could be even more important
when the ACR50 response criteria are considered.
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OBJECTIVES: To explore the relationship between dose changes
and costs in rheumatoid arthritis (RA) patients treated with
inﬂiximab. METHODS: A 5-year retrospective study using the
Medstat MarketScan database was conducted. The sample con-
sisted of patients who had a diagnosis of RA (ICD-9 = 714.xx);
at least three administrations of inﬂiximab between 1999 and
2005; no history of using anti-tumor necrosis factors for at least
6-month prior to the index infusion, and continuous enrollment
for at least 12 months after the index infusion. Per-member-per-
month (PMPM) medical and pharmacy costs were compared
among three patient cohorts: increase, decrease, and no change in
dose between the ﬁrst and the last doses in the study period.
Differences in costs were conducted controlling for age, gender,
and a health risk-adjuster score. The cost of adverse events could
not be identiﬁed separately in this analysis. RESULTS: Among
2318 patients included in the study, 685 (29.6%) had decreased
their dose, 627 (27.0%) had no change, and 1006 (43.4%) had
increased their dose during the study. Average age was 57.2
years. Patients in the no-change group were younger than
patients in the other two groups (mean age 55.6 vs. 60.1 and
57.2). Over two-thirds of patients in each group were female.
The no-change group had higher PMPM medical and pharmacy
costs ($2236.90 and $211.94) compared with the increased dose
($1719.80 and $186.09) and decreased dose groups ($1326.90
and $183.64). The difference in PMPM medical costs was sig-
niﬁcant after adjusting for age, gender, and risk score. PMPM
pharmacy costs were not statistically different. CONCLUSION:
Patients with no change in dose had the highest medical costs.
However there were no signiﬁcant differences in pharmacy costs.
Further research to explore the reasons for the differences in
medical costs and the impact of dose changes on clinical and
humanistic outcomes is recommended.
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OBJECTIVES: To evaluate the impact of anti-tumor necrosis
factor (TNF) therapy on health care costs in rheumatoid arthritis
(RA) patients. METHODS: Two groups of patients were identi-
ﬁed using claims data from Blue Cross Blue Shield health plans:
Group A-RA patients who initiated anti-TNF therapy (adali-
mumab, etanercept or inﬂiximab) between January 1, 2003 and
June 30, 2005; Group B-RA patients without anti-TNF therapy.
The groups were matched for gender, age and geographic region
(3 controls: 1 anti-TNF user). The index date for Group A was
deﬁned as the date of ﬁrst anti-TNF therapy; Group B patients
were assigned the index date of their matched case. All patients
were continuously enrolled for >=6 months before and >=12
months after the index date. RA-related and total health care
expenditures, excluding anti-TNF drug cost, were calculated for
the pre- and post-index periods. Multivariate analyses, control-
ling for potential confounders, were performed to compare per-
member-per-month (PMPM) expenditures. RESULTS: In total,
9545 RA patients were included (2405 in Group A and 7140 in
Group B); 70.5% were female and the average age was 48.0
years. In the pre-index period, Group A had higher RA-related
PMPM ($211 versus $32, p < 0.0001) and total health care costs
($711 versus $503, p < 0.0001) than Group B. Compared with
the pre-index period, RA-related PMPM costs (excluding anti-
TNF drugs) decreased for Group A by $44 (-20.9%) but
increased for Group B by $3 (+9.5%) (p = 0.0332) during the
post-index period. After adjusting for confounding variables,
RA-related cost differences from pre- to post-index period
remained between anti-TNF users and controls (p = 0.0049).
CONCLUSION: Although their pre-index RA-related costs were
signiﬁcantly higher, post-index RA-related costs (excluding anti-
TNF drug costs) of RA anti-TNF users decreased signiﬁcantly
from pre-index costs compared with RA non-anti-TNF user
costs. Additional analyses using clinical and quality-of-life
measures are needed to determine the effectiveness of anti-TNF
therapies.
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OBJECTIVES: To evaluate the cost-effectiveness of rituximab
compared to abatacept for the treatment of moderate/severe RA
patients following the failure of one previous TNF-inhibitor from
the perspective of the UK. METHODS: A cost-utility approach
was adopted, evaluating the total direct NHS costs and QALYs.
Baseline patient characteristics were based on the REFLEX phase
III trial. A micro-simulation model of 10,000 RA patients esti-
mated lifetime Health Assessment Questionnaire (HAQ) progres-
sion, QALYs and direct costs. The starting time-point of the
model was upon commencement of treatment with abatacept or
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rituximab, following the failure of one previous TNF inhibitor.
Upon treatment failure it was assumed patients would follow an
identical lifetime treatment strategy consisting of: leﬂunomide,
gold, cyclosporine and palliative care. As is currently recom-
mended by NICE no second TNF inhibitor was assumed to be
administered. Rituximab was assumed to be administered every
9 months for responding patients. ACR response rates were
taken from the respective phase III RCTs and adjusted for
placebo response. The initial HAQ drop by ACR category was
taken from the REFLEX RCT, with long-term HAQ progression
from published literature. RESULTS: Annual drug acquisition
and administration costs were lower for rituximab compared to
abatacept. Discounted total lifetime direct NHS costs were
£46,570 and £63,055 for the rituximab and abatacept groups
respectively. Rituximab generated a discounted cost-saving of
£16,485 per patient due to reduced drug acquisition and admin-
istration costs. Total QALYs were estimated as 3.879 and 3.812
for rituximab and abatacept, respectively. CONCLUSION: The
model predicted that rituximab dominated abatacept for RA
patients who have failed one previous TNF inhibitor therapy,
with higher estimated QALYs and lower NHS costs. Due to
lower drug administration requirements rituximab may also gen-
erate a capacity beneﬁt to the NHS compared with abatacept,
through lower annual infusion and outpatient requirements.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic autoim-
mune disorder associated with substantial health and economic
burden. We describe a cost-utility model developed to assess the
cost-utility of Abatacept in the treatment of RA in the UK (NHS).
METHODS: A probabilistic patient level simulation model was
developed to estimate long-term costs and health outcomes of
abatacept versus methotrexate (MTX) in RA patients who failed
anti-TNF therapy. The model predicted patients’ HAQ (Health
Assessment Questionnaire) scores over time based on the initial
response to treatment (% change in HAQ at six months).
Patients with an inadequate response (failure to achieve a speci-
ﬁed reduction in HAQ score) ended treatment at this point.
Responding patients continued treatment with a reduced rate of
HAQ progression until long-term treatment failure—modelled as
an exponential process. On long term treatment failure, patients’
HAQ was assumed to worsen by amount equal to their initial
improvement. Efﬁcacy and adverse events rates were obtained
from a randomized clinical trial. Costs, utility and annual mor-
tality rates (AMR) were estimated as a function of HAQ.
RESULTS: Compared to MTX, Abatacept treatment results in
1.6 additional QALYs at an additional cost of £40,371, giving an
ICER of £25,395/QALY, a value in line with other biologic
treatments recommended for use in the UK. Results were stable
under a range of sensitivity analyses. CONCLUSION: Compared
to MTX, Abatacept is a cost-effective treatment for patients who
failed anti-TNF therapy. The use of a patient level simulation
allows costs and utilities to be estimated as non-linear functions
of HAQ and for the AMR to be conditioned on patient’s HAQ
scores. The model was implemented in R and was sufﬁciently fast
for probabilistic analysis. This allowed two key requirements for
decision-making to be met: unbiased estimates of costs and
effects and an assessment of the decision uncertainty.
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OBJECTIVES: The targeted B-cell therapy rituximab (RTX) is
registered for patients with rheumatoid arthritis (RA) who have
had inadequate response or intolerance to one or more TNF-
alpha blocking agents. The only third payer in Hungary, the
National Health Insurance Found required economic data about
RTX treatment for reimbursement decision. The aim of our study
was to estimate the cost-effectiveness of RTX in Hungarian
context in RA patients who failed anti-TNF therapy.
METHODS: We developed a Markov model to perform a cost-
utility analysis. Cost per quality adjusted life year (QALY) gain
was assessed. RTX was compared with traditional treatment
(DMARDs) in the model. Model states were deﬁned by ACR
responses. Baseline characteristics of the patient population and
clinical efﬁcacy were based on international data, the REFLEX
trial. Costs of rituximab (drug therapy, administration and moni-
toring) were calculated based on ofﬁcial Hungarian price list. RA
related costs were taken from a previous Hungarian cost-of-
illness study considering disease levels by HAQ. Utility was
derived using the equation between HAQ and EQ-5D from a
Hungarian survey of RA patients. The time horizon of the model
was lifetime. Cost effectiveness analysis was performed for one
year RTX treatment. The model used a societal perspective
including all costs. RESULTS: One year long RTX treatment (9
month between courses) results in 0.228 QALY gain compared
with traditional treatment in lifetime perspective. Incremental
total costs were 6,224 Euros, cost-effectiveness ratio was 27,258
Euros/QALY. Cost-effectiveness of two years long RTX treat-
ment is 23,182 Euros/QALY. Increasing the duration of treat-
ment resulted better cost-effectiveness ratio. CONCLUSION:
Cost-effectiveness of RTX is under the commonly used ﬁnancing
threshold (30,000€/QALY), although RTX was compared with
low cost traditional treatment. Hungarian cost-effectiveness ratio
may be higher than the European average because drug costs are
comparable but medical costs are lower in Hungary than in the
EU.
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OBJECTIVES: Evaluate the impact of persistence with anti-TNF
treatment on total health care and medical costs among patients
with psoriatic arthritis (PsA). METHODS: A retrospective study
was conducted using the US PharMetrics managed-care-plan
database from January 2000 through June 2005. Patients con-
tinuously enrolled for 6 months pre- and 12 months post-index
biologic date and having 2 distinct claims for PsA were included.
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